Economic analyses of human genetics services: A systematic review

Carlson, Josh J.; Henrikson, Nora B.; Veenstra, David L.; Ramsey, Scott D.

doi:10.1097/01.gim.0000182467.79495.e2

Cited by 50 publications

(37 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the mean quality score from this review (89.77) was 2.72 points higher than the mean quality score from the review by Carlson et al 5 (87.05), this difference is not statistically significant (P value Ͻ0.35).…”

Section: Quality Of Included Studiescontrasting

confidence: 48%

“…We used the same search terms and databases as Carlson et al, 5 which included terms as follows: "cost-effectiveness," "cost-benefit," "cost-minimization," "cost-utility," "economics," "gene therapy," "pharmacogenetics," "genetic screening," and "genotype" and used databases such as PubMed, Medline, Proquest, LexisNexis, Expanded Academic Index, The Harvard Review of Economic Analyses (http://www.hsph.harvard.edu/cearegistry/), PsycINFO, National Institute for Clinical Excellence (http://www.nice.org.uk), and the Canadian Agency for Drugs and Technologies in Health (http://www.cadth.ca/index.php/en/home).…”

Section: Methodsmentioning

confidence: 99%

“…Once scores were obtained using the QHES grading system, the overall mean and subgroup means were calculated and compared with those reported by Carlson et al 5 The difference between mean scores was assessed for statistical significance using a one sample t test. Because the magnitude of the quality score is based on the deduction of points for missed criteria, the number of studies that failed to address each quality criterion was tracked to identify major contributors to poor quality scores in the reviewed studies.…”

Section: Methodsmentioning

confidence: 99%

“…Conclusions for studies in similar clinical areas were summarized. ICERs extracted in this review and those cited by Carlson et al 5 were graphed to observe trends through time. Each article identified through the literature review was also assessed for quality by two reviewers (S.D.…”

Section: Methodsmentioning

confidence: 99%

“…This is particularly true of genetic testing and services, an area now undergoing an unprecedented pace of new discovery with potential clinical application. 4 By reviewing economic evaluations of genetic testing services published between January 1990 and August 2004, Carlson et al 5 provided meaningful insight into the quality and interpretation of such studies. Since 2004, there have been a considerable number of economic evaluations published on genetic testing and interventions; however, there have been few published reviews on the health economic evidence pertaining to these types of investments.…”

mentioning

confidence: 99%

See 4 more Smart Citations

A review of economic evaluations of genetic testing services and interventions (2004–2009)

Djalalov

Musa

Mendelson³

et al. 2011

Genetics in Medicine

View full text Add to dashboard Cite

Abstract:To review economic evaluations of genetic interventions published between 2004 and 2009 and assess the quality of the identified studies, we searched for economic evaluations of genetic testing and interventions published between 2004 and 2009. Studies that met inclusion criteria were reviewed and their quality then assessed using a validated instrument-the Quality of Health Economic Studies. Of 54 articles identified, 26 met study criteria and were included in the review. These studies span a number of clinical indications, genetic tests, and interventions, but the majority (92%) focuses on genetic interventions for preventive screening and increasing treatment efficacy. The mean quality score for the reviewed studies was 89.8. Comparison of the quality of different study types revealed that cost-utility studies and studies that used a combined decision tree and Markov model had the highest mean quality scores. Clear statements regarding bias, funding source, and study perspective were commonly lacking in the reviewed studies. Although the reviewed studies were of fairly high quality, we found Quality of Health Economic Studies methodology for grading the quality of economic evaluations challenging and observed no statistically significant improvement in quality of studies between the periods

show abstract

Section: Quality Of Included Studiescontrasting

confidence: 48%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

A review of economic evaluations of genetic testing services and interventions (2004–2009)

Djalalov

Musa

Mendelson³

et al. 2011

Genetics in Medicine

View full text Add to dashboard Cite

show abstract

Personalized Medicine

Ayer

Chen

2018

Handbook of Healthcare Analytics

View full text Add to dashboard Cite

Valuing the Economic Benefits of Complex Interventions: When Maximising Health Is Not Sufficient

2012

View full text Add to dashboard Cite

Complex interventions, involving interlinked packages of care, challenge the application of current methods of economic evaluation that focus on measuring only health gain. Complex interventions may be problematic on two levels. The complexity means the intervention may not fit into one of the current appraisal systems, and/or maximising health is not the only objective. This paper discusses the implications of a programme of work that focused on clinical genetics services, as an example of a complex intervention, and aimed to identify the following: the attributes that comprise both health and non-health aspects of benefits and whether it is possible to evaluate such an intervention using current National Institute for Health and Clinical Excellence appraisal processes. Genetic services and tests are a good example of a complex intervention and have broader objectives than just health gain, which may usefully be measured using the concept related to capability, which we have called 'empowerment'. Further methodological work is required to identify the trade-off between non-health (empowerment) and health benefits for other complex interventions. We do not advocate a move away from QALY maximisation but do suggest that there is a need for a more considered approach that can take account of the perceived value for non-health attributes for some complex interventions.

show abstract

Economic analyses of human genetics services: A systematic review

Cited by 50 publications

References 20 publications

A review of economic evaluations of genetic testing services and interventions (2004–2009)

A review of economic evaluations of genetic testing services and interventions (2004–2009)

Personalized Medicine

Valuing the Economic Benefits of Complex Interventions: When Maximising Health Is Not Sufficient

Contact Info

Product

Resources

About